<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:40:30Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10693876" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10693876</identifier>
        <datestamp>2023-12-04</datestamp>
        <setSpec>jimmthercanc</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id>
              <journal-id journal-id-type="hwp">jitc</journal-id>
              <journal-id journal-id-type="publisher-id">jitc</journal-id>
              <journal-title-group>
                <journal-title>Journal for Immunotherapy of Cancer</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2051-1426</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10693876</article-id>
              <article-id pub-id-type="pmcid">PMC10693876</article-id>
              <article-id pub-id-type="pmc-uid">10693876</article-id>
              <article-id pub-id-type="pmid">38040420</article-id>
              <article-id pub-id-type="pmid">38040420</article-id>
              <article-id pub-id-type="publisher-id">jitc-2023-007586</article-id>
              <article-id pub-id-type="doi">10.1136/jitc-2023-007586</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Clinical/Translational Cancer Immunotherapy</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                  <subject>2435</subject>
                </subj-group>
                <series-title>Original research</series-title>
              </article-categories>
              <title-group>
                <article-title>Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma</article-title>
              </title-group>
              <contrib-group>
                <contrib id="author-108784622" contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3870-6968</contrib-id>
                  <name>
                    <surname>Katz</surname>
                    <given-names>Matthew H G</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-73990740" contrib-type="author">
                  <name>
                    <surname>Petroni</surname>
                    <given-names>Gina R</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-108849024" contrib-type="author">
                  <name>
                    <surname>Bauer</surname>
                    <given-names>Todd</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib id="author-73517727" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4725-0459</contrib-id>
                  <name>
                    <surname>Reilley</surname>
                    <given-names>Matthew J</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib id="author-103834937" contrib-type="author">
                  <name>
                    <surname>Wolpin</surname>
                    <given-names>Brian M</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib id="author-108849067" contrib-type="author">
                  <name>
                    <surname>Stucky</surname>
                    <given-names>Chee-Chee</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib id="author-74828092" contrib-type="author">
                  <name>
                    <surname>Bekaii-Saab</surname>
                    <given-names>Tanios S</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">8</xref>
                </contrib>
                <contrib id="author-74727873" contrib-type="author">
                  <name>
                    <surname>Elias</surname>
                    <given-names>Rawad</given-names>
                  </name>
                  <xref rid="aff9" ref-type="aff">9</xref>
                </contrib>
                <contrib id="author-108849090" contrib-type="author">
                  <name>
                    <surname>Merchant</surname>
                    <given-names>Nipun</given-names>
                  </name>
                  <xref rid="aff10" ref-type="aff">10</xref>
                </contrib>
                <contrib id="author-84893005" contrib-type="author">
                  <name>
                    <surname>Dias Costa</surname>
                    <given-names>Andressa</given-names>
                  </name>
                  <xref rid="aff11" ref-type="aff">11</xref>
                </contrib>
                <contrib id="author-108849170" contrib-type="author">
                  <name>
                    <surname>Lenehan</surname>
                    <given-names>Patrick</given-names>
                  </name>
                  <xref rid="aff12" ref-type="aff">12</xref>
                  <xref rid="aff13" ref-type="aff">13</xref>
                </contrib>
                <contrib id="author-108849179" contrib-type="author">
                  <name>
                    <surname>Cardot-Ruffino</surname>
                    <given-names>Victoire</given-names>
                  </name>
                  <xref rid="aff12" ref-type="aff">12</xref>
                  <xref rid="aff13" ref-type="aff">13</xref>
                </contrib>
                <contrib id="author-74172882" contrib-type="author">
                  <name>
                    <surname>Rodig</surname>
                    <given-names>Scott</given-names>
                  </name>
                  <xref rid="aff12" ref-type="aff">12</xref>
                  <xref rid="aff13" ref-type="aff">13</xref>
                </contrib>
                <contrib id="author-87987813" contrib-type="author">
                  <name>
                    <surname>Pfaff</surname>
                    <given-names>Kathleen</given-names>
                  </name>
                  <xref rid="aff14" ref-type="aff">14</xref>
                  <xref rid="aff15" ref-type="aff">15</xref>
                </contrib>
                <contrib id="author-73322403" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2263-363X</contrib-id>
                  <name>
                    <surname>Dougan</surname>
                    <given-names>Stephanie K</given-names>
                  </name>
                  <xref rid="aff12" ref-type="aff">12</xref>
                  <xref rid="aff13" ref-type="aff">13</xref>
                </contrib>
                <contrib id="author-84877959" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0943-7407</contrib-id>
                  <name>
                    <surname>Nowak</surname>
                    <given-names>Jonathan Andrew</given-names>
                  </name>
                  <xref rid="aff12" ref-type="aff">12</xref>
                  <xref rid="aff13" ref-type="aff">13</xref>
                </contrib>
                <contrib id="author-74335049" contrib-type="author">
                  <name>
                    <surname>Varadhachary</surname>
                    <given-names>Gauri R</given-names>
                  </name>
                  <xref rid="aff16" ref-type="aff">16</xref>
                </contrib>
                <contrib id="author-73322215" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6664-4373</contrib-id>
                  <name>
                    <surname>Slingluff</surname>
                    <given-names>Craig L</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib id="author-108849237" contrib-type="author">
                  <name>
                    <surname>Rahma</surname>
                    <given-names>Osama</given-names>
                  </name>
                  <xref rid="aff11" ref-type="aff">11</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label><institution content-type="department">Department of Surgical Oncology</institution>, <institution specific-use="Ringgold_4002">The University of Texas MD Anderson Cancer Center</institution>, <addr-line content-type="city">Houston</addr-line>, <addr-line content-type="state">Texas</addr-line>, <country>USA</country></aff>
              <aff id="aff2"><label>2</label><institution content-type="department">Division of Translational Research and Applied Statistics, Department of Public Health Sciences</institution>, <institution specific-use="Ringgold_12349">University of Virginia Health System</institution>, <addr-line content-type="city">Charlottesville</addr-line>, <addr-line content-type="state">Virginia</addr-line>, <country>USA</country></aff>
              <aff id="aff3"><label>3</label><institution content-type="department">Department of Surgery</institution>, <institution specific-use="Ringgold_12350">University of Virginia Health System</institution>, <addr-line content-type="city">Charlottesville</addr-line>, <addr-line content-type="state">Virginia</addr-line>, <country>USA</country></aff>
              <aff id="aff4"><label>4</label><institution content-type="department">Division of Hematology and Oncology, Department of Medicine</institution>, <institution specific-use="Ringgold_12350">University of Virginia Health System</institution>, <addr-line content-type="city">Charlottesville</addr-line>, <addr-line content-type="state">Virginia</addr-line>, <country>USA</country></aff>
              <aff id="aff5"><label>5</label><institution content-type="department">Department of Medical Oncology</institution>, <institution specific-use="Ringgold_1855">Dana-Farber Cancer Institute</institution>, <addr-line content-type="city">Boston</addr-line>, <addr-line content-type="state">Massachusetts</addr-line>, <country>USA</country></aff>
              <aff id="aff6"><label>6</label><institution content-type="department">Department of Medicine</institution>, <institution specific-use="Ringgold_1811">Harvard Medical School</institution>, <addr-line content-type="city">Boston</addr-line>, <addr-line content-type="state">Massachusetts</addr-line>, <country>USA</country></aff>
              <aff id="aff7"><label>7</label><institution content-type="department">Department of Surgery</institution>, <institution specific-use="Ringgold_6915">Mayo Clinic</institution>, <addr-line content-type="city">Rochester</addr-line>, <addr-line content-type="state">Minnesota</addr-line>, <country>USA</country></aff>
              <aff id="aff8"><label>8</label><institution content-type="department">Division of Hematology and Medical Oncology, Department of Internal Medicine</institution>, <institution>Mayo Clin</institution>, <addr-line content-type="city">Phoenix</addr-line>, <addr-line content-type="state">Arizona</addr-line>, <country>USA</country></aff>
              <aff id="aff9"><label>9</label><institution>Hartford HealthCare Cancer Institute</institution>, <addr-line content-type="city">Plainville</addr-line>, <addr-line content-type="state">Connecticut</addr-line>, <country>USA</country></aff>
              <aff id="aff10"><label>10</label><institution content-type="department">Department of Surgery</institution>, <institution specific-use="Ringgold_5452">University of Miami</institution>, <addr-line content-type="city">Coral Gables</addr-line>, <addr-line content-type="state">Florida</addr-line>, <country>USA</country></aff>
              <aff id="aff11"><label>11</label><institution content-type="department">Department of Medical Oncology</institution>, <institution>Dana-Farber Cancer Institute and Harvard Medical School</institution>, <addr-line content-type="city">Boston</addr-line>, <addr-line content-type="state">Massachusetts</addr-line>, <country>USA</country></aff>
              <aff id="aff12"><label>12</label><institution content-type="department">Department of Cancer Immunology and Virology</institution>, <institution specific-use="Ringgold_1855">Dana-Farber Cancer Institute</institution>, <addr-line content-type="city">Boston</addr-line>, <addr-line content-type="state">Massachusetts</addr-line>, <country>USA</country></aff>
              <aff id="aff13"><label>13</label><institution content-type="department">Department of Immunology</institution>, <institution specific-use="Ringgold_1811">Harvard Medical School</institution>, <addr-line content-type="city">Boston</addr-line>, <addr-line content-type="state">Massachusetts</addr-line>, <country>USA</country></aff>
              <aff id="aff14"><label>14</label><institution content-type="department">Center for Immuno-Oncology</institution>, <institution specific-use="Ringgold_1855">Dana-Farber Cancer Institute</institution>, <addr-line content-type="city">Boston</addr-line>, <addr-line content-type="state">Massachusetts</addr-line>, <country>USA</country></aff>
              <aff id="aff15"><label>15</label><institution content-type="department">Department of Pathology</institution>, <institution>Brigham and Women’s Hospital</institution>, <addr-line content-type="city">Boston</addr-line>, <addr-line content-type="state">Massachusetts</addr-line>, <country>USA</country></aff>
              <aff id="aff16"><label>16</label><institution content-type="department">Department of Gastrointestinal Medical Oncology</institution>, <institution specific-use="Ringgold_4002">University of Texas MD Anderson Cancer Center</institution>, <addr-line content-type="city">Houston</addr-line>, <addr-line content-type="state">Texas</addr-line>, <country>USA</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Dr Matthew H G Katz; <email>mhgkatz@mdanderson.org</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>1</day>
                <month>12</month>
                <year>2023</year>
              </pub-date>
              <volume>11</volume>
              <issue>12</issue>
              <elocation-id>e007586</elocation-id>
              <history>
                <date date-type="accepted">
                  <day>18</day>
                  <month>10</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <ali:free_to_read/>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense" start_date="2023-12-01">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="jitc-2023-007586.pdf"/>
              <abstract>
                <sec>
                  <title>Background</title>
                  <p>Pancreatic ductal adenocarcinoma (PDAC) is a challenging target for immunotherapy because it has an immunosuppressive tumor microenvironment. Neoadjuvant chemoradiotherapy can increase tumor-infiltrating lymphocyte (TIL) density, which may predict overall survival (OS). We hypothesized that adding programmed cell death protein 1 (PD-1) blockade to chemoradiotherapy would be well tolerated and increase TILs among patients with localized PDAC.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>Patients were randomized 2:1 to Arm A (receiving pembrolizumab plus chemoradiotherapy (capecitabine and external beam radiation)) or Arm B (receiving chemoradiotherapy alone) before anticipated pancreatectomy. Primary endpoints were (1) incidence and severity of adverse events during neoadjuvant therapy and (2) density of TILs in resected tumor specimens. TIL density was assessed using multiplexed immunofluorescence histologic examination.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>Thirty-seven patients were randomized to Arms A (n=24) and B (n=13). Grade ≥3 adverse events related to neoadjuvant treatment were experienced by 9 (38%) and 4 (31%) patients in Arms A and B, respectively, with one patient experiencing dose-limiting toxicity in Arm A. Seventeen (71%) and 7 (54%) patients in Arms A and B, respectively, underwent pancreatectomy. Median CD8<sup>+</sup> T-cell densities in Arms A and B were 67.4 (IQR: 39.2–141.8) and 37.9 (IQR: 22.9–173.4) cells/mm<sup>2</sup>, respectively. Arms showed no noticeable differences in density of CD8<sup>+</sup>Ki67<sup>+</sup>, CD4<sup>+</sup>, or CD4<sup>+</sup>FOXP3<sup>+</sup> regulatory T cells; M1-like and M2-like macrophages; or granulocytes. Median OS durations were 27.8 (95% CI: 17.1 to NR) and 24.3 (95% CI: 12.6 to NR) months for Arms A and B, respectively.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>Adding pembrolizumab to neoadjuvant chemoradiotherapy was safe. However, no convincing effect on CD8<sup>+</sup> TILs was observed.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>Immunotherapy</kwd>
                <kwd>Adjuvants, Immunologic</kwd>
                <kwd>Clinical Trials as Topic</kwd>
                <kwd>Combined Modality Therapy</kwd>
                <kwd>Immune Checkpoint Inhibitors</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution>Francois Wallace Monahan Fund in loving memory of Michael Insel</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-2">
                  <funding-source>
                    <institution-wrap>
                      <institution>NIH Grants</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>P50 CA127003</award-id>
                  <award-id>U01 CA210171</award-id>
                  <award-id>U01 CA274276-01</award-id>
                </award-group>
                <award-group id="funding-3">
                  <funding-source>
                    <institution-wrap>
                      <institution>Wexler Family Fund</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-4">
                  <funding-source>
                    <institution-wrap>
                      <institution>Dana-Farber Cancer Institute Hale Family Center for Pancreatic Cancer Research</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-5">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001784</institution-id>
                      <institution>Pancreatic Cancer Action Network</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-6">
                  <funding-source>
                    <institution-wrap>
                      <institution>Lustgarten Foundation dedicated laboratory program</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-7">
                  <funding-source>
                    <institution-wrap>
                      <institution>Noble Effort Fund</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-8">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004334</institution-id>
                      <institution>Merck</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-9">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id>
                      <institution>National Institute of General Medical Sciences</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>T32GM007753</award-id>
                  <award-id>T32GM144273</award-id>
                </award-group>
                <award-group id="funding-10">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009730</institution-id>
                      <institution>Stand Up To Cancer</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-11">
                  <funding-source>
                    <institution-wrap>
                      <institution>DFCI Hale Family Center for Pancreatic Cancer Research</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <boxed-text id="BX1" position="float">
              <sec>
                <title>WHAT IS ALREADY KNOWN ON THIS TOPIC</title>
                <list list-type="bullet">
                  <list-item>
                    <p>Although many strategies have been studied to improve the response of pancreatic ductal adenocarcinoma (PDAC) to immunotherapy, none have translated to clinical benefit.</p>
                  </list-item>
                </list>
              </sec>
              <sec>
                <title>WHAT THIS STUDY ADDS</title>
                <list list-type="bullet">
                  <list-item>
                    <p>We hypothesized that chemoradiotherapy (CRT) could be used safely to prime the immune microenvironment and that a combination of CRT and immune checkpoint inhibition with a programmed cell death protein 1 (PD-1) inhibitor would increase tumor-infiltrating lymphocytes (TILs’) ability to overcome the primary resistance of PDAC to PD-1 blockade. In this study, neoadjuvant PD-1 blockade concurrent with chemoradiotherapy was safe in the neoadjuvant setting. However, no salient effect on CD8<sup>+</sup> TILs was observed.</p>
                  </list-item>
                </list>
              </sec>
              <sec>
                <title>HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY</title>
                <list list-type="bullet">
                  <list-item>
                    <p>Future work regarding novel drug combinations should focus not only on priming adaptive immune responses but also targeting the PDAC immunosuppressive microenvironment.</p>
                  </list-item>
                </list>
              </sec>
            </boxed-text>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>Over 60,000 people in the USA were diagnosed with pancreatic ductal adenocarcinoma (PDAC) in 2021, and only about 6,000 (10%) have a projected survival of 5 years or more.<xref rid="R1" ref-type="bibr">1</xref> Resection of pancreatic tumors and associated lymph nodes via pancreatectomy may cure PDAC in upwards of 20% of patients; however, fewer than 20% of newly diagnosed patients have operable cancers, and most patients who do undergo surgery subsequently develop incurable, recurrent disease.<xref rid="R2" ref-type="bibr">2</xref> Neoadjuvant therapy is frequently administered to patients with resectable or borderline resectable PDAC to improve systemic disease control, increase the likelihood of a complete resection, and determine which patients will most likely benefit from surgery.<xref rid="R3" ref-type="bibr">3</xref></p>
              <p>Neoadjuvant therapy has historically consisted of chemotherapy, chemoradiotherapy (CRT), or both, but interest in the administration of immune checkpoint inhibitors in this setting has increased.<xref rid="R4" ref-type="bibr">4 5</xref> Unfortunately, immune checkpoint inhibitors appear ineffective in most PDAC cases, as they have shown effectiveness in only the &lt;1% of cases with microsatellite instability. This poor response may be due at least in part to the lack of activated intratumoral T cells and the complex immunosuppressive tumor microenvironment (TME) being dominated by myeloid-derived suppressor cells, regulatory T cells, and cancer-associated fibroblasts.<xref rid="R6" ref-type="bibr">6–12</xref> Increased density of tumor-infiltrating lymphocytes (TILs) and tumor-neoantigen-specific memory CD8<sup>+</sup> T cells has been associated with increased longevity of patients with PDAC, suggesting that priming the TME may improve the activity of immune checkpoint inhibitors.<xref rid="R13" ref-type="bibr">13–15</xref></p>
              <p>CRT can enhance major histocompatability complex (MHC) class I expression in tumor cells, thereby increasing their immunogenic properties. Tumor cells can then undergo immunogenic cell death that can release tumor antigens, activate local dendritic cells to migrate to the draining lymph nodes, and increase CD4<sup>+</sup> and CD8<sup>+</sup> T-cell priming.<xref rid="R16" ref-type="bibr">16–18</xref> However, the ability of cancer cells to evade antitumor T-cell activity is controlled by immune checkpoint inhibitors such as programmed death-ligand 1 (PD-L1), which is expressed on both pancreatic cancer cells and immunosuppressive myeloid cells and is further induced by chemotherapies such as 5-fluorouracil and radiation therapy.<xref rid="R19" ref-type="bibr">19–21</xref>Whether CRT can be combined with PD-1 inhibitors to increase cancer cell susceptibility to treatment remains unknown.</p>
              <p>We hypothesized that CRT could be used safely to prime the immune microenvironment and that a combination of CRT and immune checkpoint inhibition (specifically, a PD-1 inhibitor) would increase TILs’ ability to overcome the primary resistance of PDAC to PD-1 blockade. To test this hypothesis, we performed a prospective, multicenter, randomized controlled trial to assess the safety and preliminary estimates of the efficacy of treatment with neoadjuvant CRT with pembrolizumab compared with neoadjuvant CRT alone in patients with resectable or borderline resectable PDAC.</p>
            </sec>
            <sec id="s2">
              <title>Patients and methods</title>
              <sec id="s2-1">
                <title>Study design</title>
                <p>This was a prospective, open-label, Phase Ib/II randomized clinical trial (ClinicalTrials.gov identifier NCT02305186) with 2:1 patient allocation to the treatment (Arm A) and control (Arm B) arms. Arm A consisted of treatment with a combination of pembrolizumab and CRT (the 5-fluorouracil-based drug capecitabine and external-beam radiotherapy), and Arm B consisted of treatment with CRT alone. The primary endpoints were (1) the incidence and severity of adverse events (AEs) during neoadjuvant therapy and (2) the relative density of CD8<sup>+</sup> TILs in resected tumor specimens. Secondary endpoints were treatment effect, progression-free survival (PFS), recurrence-free survival (RFS), and overall survival (OS).</p>
                <p>The study was conducted at six sites: University of Virginia, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Mayo Clinic, Hartford HealthCare Cancer Center, and University of Miami.</p>
              </sec>
              <sec id="s2-2">
                <title>Inclusion criteria</title>
                <p>Inclusion criteria comprised the presence of resectable or borderline resectable PDAC as classified according to the Alliance for Clinical Trials in Oncology criteria, with measurable disease identified by the Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 guidelines and an Eastern Cooperative Oncology Group performance score of 0 or 1.<xref rid="R22" ref-type="bibr">22</xref> Exclusion criteria comprised the presence of metastatic disease; administration of immunosuppressive therapy within 7 days of the first trial treatment; and prior surgery, chemotherapy, targeted small-molecule therapy, immunotherapy, or radiation therapy for pancreatic cancer.</p>
              </sec>
              <sec id="s2-3">
                <title>Protocol therapy and follow-up</title>
                <p>Patients in both arms received CRT consisting of concurrent capecitabine (825 mg/m<sup>2</sup> orally two times a day) and external-beam radiation (50.4 Gy in 28 fractions, 5 days per week), starting on day 1. Patients in Arm A also received 200 mg of intravenous pembrolizumab every 3 weeks on days 1, 22, and 43.</p>
                <p>A restaging CT scan was performed 4–6 weeks after completion of the neoadjuvant regimen. Patients without significant radiographic evidence of local or distant disease progression were scheduled to undergo pancreatectomy within 2 weeks of the restaging scan. Following pancreatectomy, patients were treated with adjuvant therapy at the discretion of their treating oncologist. The study design is shown schematically in <xref rid="F1" ref-type="fig">figure 1</xref>. Patients were followed-up every 4 months after the end of treatment until they reached 24 months post-registration.</p>
                <fig position="float" id="F1">
                  <label>Figure 1</label>
                  <caption>
                    <p>Schematic illustration of study design. Patients with histologically confirmed resectable or borderline resectable pancreatic ductal adenocarcinoma were enrolled and randomized in a 2:1 ratio to receive CRT plus pembrolizumab or CRT alone prior to anticipated pancreatectomy. During neoadjuvant therapy, peripheral blood mononuclear cells were collected for analysis by flow cytometry. At pancreatectomy, tissue was collected for analysis by immunofluorescence imaging. Patients were followed for 2 years while receiving adjuvant chemotherapy at the discretion of their treating oncologist. CRT, chemoradiotherapy.</p>
                  </caption>
                  <graphic xlink:href="jitc-2023-007586f01" position="float"/>
                </fig>
              </sec>
              <sec id="s2-4">
                <title>Clinical assessment</title>
                <p>Radiologic response at each institution was evaluated using the RECIST V.1.1 guidelines.<xref rid="R23" ref-type="bibr">23</xref> Surgical specimen analysis was performed following recommendations of the College of American Pathologists.<xref rid="R24" ref-type="bibr">24 25</xref> Treatment effect in surgical specimens was assessed by an experienced pathologist at each study site. Treatment effect was scored as 0 (complete response, no viable cancer cells), 1 (near-complete response, single cells or rare small groups of cancer cells), 2 (partial response, residual cancer with evident tumor regression but more than single cells or rare small groups of cancer cells), or 3 (poor or no response, extensive residual cancer with no evident tumor regression).</p>
                <p>AEs were graded using the Common Terminology Criteria for Adverse Events V.4.0 and were monitored from the start of neoadjuvant treatment to 30 days following surgery or, among patients who did not undergo resection, to 30 days following the date of the restaging scan or anticipated surgery.<xref rid="R26" ref-type="bibr">26</xref> Participants treated on Arm A were also monitored for dose-limiting toxicities (DLTs) prior to surgery and for readmission within 30 days following surgery for events related to the combination.</p>
              </sec>
              <sec id="s2-5">
                <title>Assessment of the tumor immune microenvironment</title>
                <p>Formalin-fixed paraffin-embedded (FFPE) tissue from surgical resection specimens with residual tumor was analyzed using multiplexed immunofluorescence (mIF), digital image analysis, and machine learning to identify immune cell subsets in the TME. Three mIF antibody panels optimized for PDAC were used for analysis of T cells (CD4, CD8, FOXP3, Ki67), myeloid cell subsets and ARG-1 immunosuppressive potential (CD15, CD14, ARG1, HLA-DR, CD33), and macrophage polarization status (IRF5, CD163, CD68, CD86, MRC1 (CD206)); suppliers and dilution are provided in <xref rid="SP1" ref-type="supplementary-material">online supplemental table S1</xref>. All panels included 2-(4-amidinophenyl)−1H-indole-6-carboxamidine (DAPI) as a nuclear marker and anti-cytokeratin to identify epithelial cells. Methodologic details for the myeloid cell subset and macrophage polarization panels have been previously published, while the T-cell panel was specifically built for this study using previously validated antibodies.<xref rid="R27" ref-type="bibr">27 28</xref> In brief, staining was performed using Leica BOND RX Research Stainer (Leica Biosystems, Buffalo, Illinois, USA). Slides stained for the T-cell panel were digitized using a Mantra 2 multispectral imaging system (Akoya Biosciences, Hopkinton, Massachusetts, USA), while myeloid cell subset and macrophage polarization slides were digitized using a Vectra V.3.0 multispectral imaging system (Akoya Biosciences). For each slide, an average of 4 (range: 2–10) representative regions of interest containing residual, morphologically viable tumor epithelium were scanned at 200× magnification. Multispectral images were unmixed and processed to generate single-cell phenotypes using the <italic toggle="yes">inForm</italic> software package (Akoya Biosciences). The resultant single-cell level data were further analyzed using R V.4.0 (R Foundation for Statistical Computing, Vienna, Austria) to generate cell density measurements. Region-level density measurements from each panel were averaged to produce patient-level immune cell density measurements.</p>
                <supplementary-material id="SP1" position="float" content-type="local-data">
                  <object-id pub-id-type="doi">10.1136/jitc-2023-007586.supp1</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="SS1" xlink:href="jitc-2023-007586supp001.pdf" content-type="local-data"/>
                  </p>
                </supplementary-material>
                <p>Immunohistochemical analysis of PD-L1 was conducted on FFPE specimens using a monoclonal anti-PD-L1 antibody (clone E1L3N, Cell Signaling Technology, Danvers, Massachusetts, USA, dilution 1:100). PD-L1 expression was assessed by determining the Tumor Proportion Score (TPS) and Combined Positive Score (CPS) across all viable tumor-containing regions of each slide.</p>
              </sec>
              <sec id="s2-6">
                <title>Flow cytometry</title>
                <p>Flow cytometric analyses of peripheral blood mononuclear cells (PBMCs) were conducted during neoadjuvant therapy to study the impact of CRT with and without pembrolizumab on peripheral immune cell populations. PBMCs were thawed at 37°C and transferred into 15 mL Falcon tubes containing 10 mL of Roswell Park Memorial Institute (RPMI) medium (Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco) and DNase I (2 U/mL, Sigma-Aldrich). These tubes were centrifuged at 350×g for 5 min at 4°C. Cell pellets were resuspended in 1 mL of fluorescence-activated cell-sorting (FACS) buffer (phosphate-buffered saline with 10% FBS and 2 mM EDTA). Each cell suspension was transferred into two Eppendorf DNA LoBind tubes, which were centrifuged at 350×g for 5 min at 4°C. The supernatant was discarded, and cell pellets were resuspended with 100 µL of FACS buffer and 2.5 µL of each of the following antibodies all from BioLegend: CD45RO BV650, HLADR BV570 clone L243, CD38 BV711, CD16 BV785 clone 3G8, CD14 BV605, CD45RA FITC, CX3CR1 BV421, KLRG1 PerCP-Cy5.5, CD19 AF700, CCR7 PE-Cy7, PD-1 PE, CD8 PB. After staining for 20 min at 4°C, 1 mL of FACS buffer was added to each tube, and the tubes were again centrifuged at 350×g for 5 min at 4°C. The supernatant was discarded, and the samples were fixed by adding 100 µL of 1% formalin. Flow cytometry analysis was performed using a SONY SP6800 Spectral Cell Analyzer (Sony Biotechnology, San Jose, California, USA).</p>
              </sec>
              <sec id="s2-7">
                <title>Statistical considerations and analysis</title>
                <sec id="s2-7-1">
                  <title>Randomization and sample size calculation</title>
                  <p>Participants were stratified by resectable or borderline resectable disease. Participants were then randomized in a 2:1 ratio to Arms A and B, respectively, within each stratum using a randomized block design. The intention-to-treat population was all randomized participants. The evaluable population was defined as participants who underwent pancreatectomy and had tissue available for TIL analysis. The overall target sample size of evaluable participants was 45, which was based on estimating the potential difference in the density of TILs in resected tissue between participants receiving neoadjuvant CRT in combination with pembrolizumab and participants receiving neoadjuvant CRT alone. This study was designed to obtain preliminary data on the combination and to estimate the magnitude of potential differences in immune cell populations for further research, not to directly compare endpoints between arms.</p>
                  <p>In a non-randomized study of patients with PDAC who underwent surgical resection with or without neoadjuvant CRT, the reported mean (±SD) numbers of CD8<sup>+</sup> TILs per high-powered field (hpf) were 50.1 (±38.7) in patients who underwent pancreatectomy for PDAC after receiving CRT and 24.1 (±21.3) in patients who underwent pancreatectomy for PDAC and had not received prior therapy.<xref rid="R18" ref-type="bibr">18</xref> Thus, using 38.7 as a conservative estimate of the SD of the difference in CD8<sup>+</sup> TILs before and after resection, we determined that evaluable sample sizes of 30 and 15 for Arms A and B, respectively, would produce a two-sided 95% CI for a difference of 25 TILs per hpf between arm means.</p>
                </sec>
                <sec id="s2-7-2">
                  <title>Endpoint analyses</title>
                  <p>The first primary endpoint was the incidence and severity of AEs during neoadjuvant therapy. A DLT was defined as a grade 3 or higher non-hematological or grade 4 hematological AE considered to be related to the combination of pembrolizumab and CRT or a grade 3 or higher infusion reaction due to pembrolizumab. To monitor for excessive DLT and readmission rates, the upper boundary of a sequential probability ratio test (SPRT) based on a binomial test of proportions with nominal type I and II errors of 10% each was defined separately. Results from previous studies using only neoadjuvant CRT in PDAC indicated an unacceptable rate of AEs of approximately 5% and provided the basis for an SPRT contrasting a 5% versus 25% DLT rate.<xref rid="R29" ref-type="bibr">29</xref> A readmission rate following pancreatoduodenectomy in the USA of 21.3% (95% CI: 19% to 24%) provided the basis for an SPRT contrasting a 20% and 36% 30-day readmission rate.<xref rid="R30" ref-type="bibr">30</xref></p>
                  <p>The second primary endpoint was the relative density of CD8<sup>+</sup> TILs in resected tumor specimens. Estimated mean differences and 95% CIs between immunologic effects before and after treatment between arms assumed a pooled variance and a t-distribution. Given that only 53% of the target sample size was achieved and that the observed variability in CD8<sup>+</sup> TILs was larger and more skewed than was assumed, quantile regression with no intercept was used to estimate median values and differences in medians with 95% CIs of immunologic effects between arms.</p>
                  <p>Secondary endpoints were treatment effect, PFS (defined as the time from start of treatment until first documentation of progression, recurrence, or death or until the date of last follow-up for those who had not had progression, recurrence, or death), RFS (defined as the time from pancreatectomy until first documentation of recurrence or death or until the date of last follow-up for those who had not had recurrence or died), and OS (defined as the time from start of treatment until death from any cause or until the date of last follow-up for those still alive). For each arm, time-to-event distributions were estimated by the Kaplan-Meier product limit method. We also calculated estimates and 95% CIs for median and yearly survival.</p>
                </sec>
              </sec>
              <sec sec-type="data-availability" id="s2-8">
                <title>Data availability</title>
                <p>The data generated in this study are available on request from the corresponding author.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s3">
              <title>Results</title>
              <sec id="s3-1">
                <title>Study population</title>
                <p>The study was designed to accrue up to 68 patients to obtain 45 evaluable participants. Between August 2015 and November 2019, 37 patients were enrolled and randomized to Arm A (n=24) and Arm B (n=13). Due to slow enrollment and perceived changes in standard of care,<xref rid="R22" ref-type="bibr">22 31</xref> the protocol was amended on December 31, 2019, to allow inclusion of patients who had previously received FOLFIRINOX, but the study was terminated because of slow accrual after the enrollment of five additional patients.</p>
                <p>This report describes the 37 patients enrolled prior to the amendment, who had not received prior therapy. The Consolidated Standards of Reporting Trials diagram is presented in <xref rid="F2" ref-type="fig">figure 2</xref>. The baseline demographic and clinical characteristics of these 37 participants are reported in <xref rid="T1" ref-type="table">table 1</xref>.</p>
                <table-wrap position="float" id="T1">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline demographics and staging information for all randomized patients (n=37)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Characteristic</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Arm A:<break/>CRT+pembrolizumab<break/>(n=24)</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Arm B:<break/>CRT<break/>(n=13)</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Total<break/>(n=37)</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Age, median years (range)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">66 (53–85)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">64 (57–79)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">66 (53–85)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Race, n (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> White</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">22 (92)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12 (92)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">34 (92)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Black or African American</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Other</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Unknown</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Ethnicity, n (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Non-Hispanic</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">20 (83)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11 (85)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">31 (84)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Hispanic or Latino</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (13)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (8)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Unknown</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2 (15)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (8)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Sex, n (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Male</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13 (54)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6 (46)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">19 (51)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Female</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11 (46)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7 (54)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">18 (49)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Clinical tumor stage, n (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Resectable</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10 (42)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6 (46)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">16 (43)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Borderline resectable</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14 (58)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7 (54)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">21 (57)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Tumor location, n (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Head/uncinate</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">17 (71)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10 (77)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">27 (73)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Body</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4 (17)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (23)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7 (19)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Body and tail</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2 (8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2 (5)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Head and body</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">TNM tumor stage, n (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> IA</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (13)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4 (11)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> IB</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5 (21)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7 (54)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12 (32)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> IIA</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7 (29)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8 (22)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> IIB</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5 (21)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6 (16)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> III</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4 (17)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (23)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7 (19)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">CA19-9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Median (range)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">108 (2–5,176)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">71 (15–675)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">106 (2–5,176)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Not elevated, n (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8 (33)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2 (15)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10 (27)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> &gt;ULN, n (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">16 (67)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11 (85)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">27 (73)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">ECOG PS, n (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> 0 (fully active)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13 (54)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7 (54)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">20 (54)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> 1 (restricted)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11 (46)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6 (46)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">17 (46)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T1_FN1">
                      <p>CRT, chemoradiation; ECOG PS, Eastern Cooperative Oncology Group performance score; TNM, tumor-nodes-metastasis; ULN, Upper Limit of Normal.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig position="float" id="F2">
                  <label>Figure 2</label>
                  <caption>
                    <p>Consolidated Standards of Reporting Trials diagram of patient groups. <sup>1</sup> Evaluable for safety endpoint (n=37). <sup>2</sup> Evaluable for immunologic endpoint (n=24). CRT, chemoradiotherapy</p>
                  </caption>
                  <graphic xlink:href="jitc-2023-007586f02" position="float"/>
                </fig>
              </sec>
              <sec id="s3-2">
                <title>Neoadjuvant therapy</title>
                <p>All 37 patients initiated CRT per-protocol. During CRT, 19 (79%) patients on Arm A and 11 (85%) patients on Arm B completed the prescribed dose of radiation.</p>
                <p>Among patients on Arm A, 19 (79%) patients received all three pembrolizumab doses per-protocol. Among the remaining 5 (21%) patients on Arm A, 4 (17%) patients received two doses, and 1 (4%) patient received one dose.</p>
              </sec>
              <sec id="s3-3">
                <title>Adverse events</title>
                <p>At least one grade 3 or higher AE considered at least possibly related to neoadjuvant treatment occurred in 9 (38%) patients in Arm A and 4 (31%) patients in Arm B (<xref rid="T2" ref-type="table">table 2</xref>). The only grade 4 AE at least possibly related to treatment was leukemia, experienced by one patient in Arm A; it was attributed to chemotherapy. Only one patient in Arm A experienced an AE that was deemed probably related to the combination of pembrolizumab and CRT and that qualified as a DLT (grade 3 elevation of alanine aminotransferase (transaminitis)). This AE resolved after withholding treatment and providing steroid therapy.</p>
                <table-wrap position="float" id="T2">
                  <label>Table 2</label>
                  <caption>
                    <p>Grade 3 and 4 AEs observed during neoadjuvant treatment (N=37)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td align="left" valign="bottom" rowspan="2" colspan="1">Adverse event</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="2"><break/>Arm A: CRT+pembrolizumab<break/>(n=24)</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="2"><break/>Arm B: CRT<break/>(n=13)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Grade 3</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Grade 4</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Grade 3</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Grade 4</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Gastrointestinal</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Diarrhea</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">2</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Nausea</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="5">Hepatic</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Transaminitis</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">1*</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="5">Hematologic</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Lymphocyte count decreased</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">7</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">4</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Leukemia</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">1†</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="5">Metabolic/nutrition</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Hypophosphatemia</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="5">Musculoskeletal</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Myalgia</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Arthralgia</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T2_FN1">
                      <p>9 Patients had a grade 3 or 4 AE; some patients had more than one.</p>
                    </fn>
                    <fn id="T2_FN2">
                      <p>*Attributed “probably” to CRT+pembrolizumab, thus qualifying as a dose-limiting toxicity.</p>
                    </fn>
                    <fn id="T2_FN3">
                      <p>†Attributed to chemotherapy.</p>
                    </fn>
                    <fn id="T2_FN4">
                      <p>AE, adverse event; CRT, chemoradiotherapy.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s3-4">
                <title>Surgery</title>
                <p>Of the 37 patients in our study, 24 patients across Arm A (n=17) and Arm B (n=7) underwent surgery and were evaluable. Following neoadjuvant therapy, 17 (71%) patients in Arm A underwent pancreatectomy while 7 (29%) patients did not due to the interval development of metastasis. In Arm B, 7 (54%) patients underwent pancreatectomy while 6 (46%) patients did not due to the interval development of metastasis (n=5, 38%) or local disease progression (n=1, 8%).</p>
                <p>Following surgery, 1 (6%) patient of the 17 patients who underwent pancreatectomy on Arm A was readmitted within 30 days of the procedure for reasons unrelated to the neoadjuvant treatment. Adjuvant chemotherapy was initiated in 16 (94%) resected patients in Arm A and 7 (100%) resected patients in Arm B. Surgical outcomes and pathologic staging information are summarized in <xref rid="SP1" ref-type="supplementary-material">online supplemental table S1</xref>. Fourteen (82%) resected patients on Arm A and 4 (57%) resected patients on Arm B had microscopically negative (R0) margins.</p>
              </sec>
              <sec id="s3-5">
                <title>Survival</title>
                <p>The median PFS durations were 18.2 (95% CI: 9.4 to 27.0) months for Arm A and 14.1 (95% CI: 2.6 to 24.3) months for Arm B (<xref rid="F3" ref-type="fig">figure 3A</xref>). The median OS durations were 27.8 (95% CI: 17.1 to NR) months for Arm A and 24.3 (95% CI: 12.6 to NR) months for Arm B (<xref rid="F3" ref-type="fig">figure 3B</xref>). Among patients who underwent pancreatectomy, the median RFS durations were 22.3 (95% CI: 13.5 to NR) months for Arm A and 21.8 (95% CI: 9.4 to NR) months for Arm B (<xref rid="F3" ref-type="fig">figure 3C</xref>).</p>
                <fig position="float" id="F3">
                  <label>Figure 3</label>
                  <caption>
                    <p>Survival analyses. Kaplan-Meier curves depicting (A) progression-free survival (PFS); (B) overall survival; and (C) recurrence-free survival of patients who underwent pancreatectomy. Arm A (CRT plus pembrolizumab) is depicted in blue while Arm B (CRT alone) is depicted in red. CRT, chemoradiotherapy.</p>
                  </caption>
                  <graphic xlink:href="jitc-2023-007586f03" position="float"/>
                </fig>
              </sec>
              <sec id="s3-6">
                <title>Immune cell infiltration in the tumor microenvironment</title>
                <p>The median CD8<sup>+</sup> T-cell densities were 67.4 (IQR: 39.3–141.8) and 37.9 (IQR: 22.9–173.4) cells/mm<sup>2</sup> in Arms A and B, respectively (difference in medians: 29.5 (95% CI: −113.7 to 52.6); <xref rid="T3" ref-type="table">table 3</xref> and <xref rid="F4" ref-type="fig">figure 4</xref>). The median CD4<sup>+</sup> T-cell densities in resected tumor specimens were 119.3 (IQR: 46.1–156.3) and 48.4 (IQR: 40.7–223.8) cells/mm<sup>2</sup> in Arms A and B, respectively (difference in medians: 70.8 (95% CI: −63.9 to 205.6)). As expected, FOXP3 was expressed in a small subset of CD4<sup>+</sup> cells, and densities of CD4<sup>+</sup>FOXP3<sup>+</sup> regulatory T cells were similar between arms. Similarly, minor subsets of both CD4<sup>+</sup> and CD8<sup>+</sup> cells expressed the proliferation marker Ki67. Resected tumor specimens from patients in Arm A showed lower median densities of CD4<sup>+</sup>Ki67<sup>+</sup> cells and higher median densities of CD8<sup>+</sup>Ki67<sup>+</sup> cells compared with those for patients in Arm B. However, no differences in T-lymphocyte population density were observed between treatment arms, nor did the ratios of CD8<sup>+</sup> to CD4<sup>+</sup> T lymphocytes differ between treatment arms.</p>
                <fig position="float" id="F4">
                  <label>Figure 4</label>
                  <caption>
                    <p>Immune landscape in resected pancreatic ductal adenocarcinoma (PDAC), stratified by treatment setting. Examples of multiplex immunofluorescence images and corresponding phenoplots for T-cell subsets, myeloid cell subsets and macrophage polarization panel in neoadjuvant chemoradiation (CRT) plus pembrolizumab-treated and neoadjuvant CRT-treated PDACs (A). Boxplots showing the distribution of overall (combined intraepithelial and stromal areas) immune cell densities in 15 neoadjuvant CRT plus pembrolizumab-treated and 7 neoadjuvant CRT-treated PDACs (B). Scale bars represent 50 µm. DAPI, 2-(4-amidinophenyl)−1H-indole-6-carboxamidine.</p>
                  </caption>
                  <graphic xlink:href="jitc-2023-007586f04" position="float"/>
                </fig>
                <table-wrap position="float" id="T3">
                  <label>Table 3</label>
                  <caption>
                    <p>Means, medians, and 95% CIs for immune cell densities within whole tissue areas (combined intraepithelial and stromal areas) in patients treated with neoadjuvant chemoradiotherapy (CRT) plus pembrolizumab or neoadjuvant CRT alone</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td align="left" valign="bottom" colspan="9" rowspan="1">Tumor immune microenvironment (cells/mm<sup>2</sup>)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="bottom" rowspan="2" colspan="1">Immune<break/>cell<break/>subset</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Arm A</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Arm B</td>
                        <td align="left" valign="bottom" colspan="2" rowspan="1">Arms A–B</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Arm A</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Arm B</td>
                        <td align="left" valign="bottom" colspan="2" rowspan="1">Arms A–B</td>
                      </tr>
                      <tr>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Mean<break/>(SD)</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Mean<break/>(SD)</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Difference<break/>mean</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">95% CI<break/>Difference mean</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Median<break/>(IQR)</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Median<break/>(IQR)</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Difference<break/>median</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">95% CI<break/>Difference median</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">T-cell panel</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n=<italic toggle="yes">17</italic></td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n=<italic toggle="yes">7</italic></td>
                        <td align="left" valign="top" colspan="2" rowspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">n=<italic toggle="yes">17</italic></td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n=<italic toggle="yes">7</italic></td>
                        <td align="left" valign="top" colspan="2" rowspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> CD8<sup>+</sup></td>
                        <td align="left" valign="top" rowspan="1" colspan="1">119.8<break/>(140.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">83.9<break/>(97.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">35.9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−70.1 to 142.0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">67.4<break/>(39.3-141.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">37.9<break/>(22.9-173.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">29.5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−89.0 to 148.0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> CD8<sup>+</sup>Ki67<sup>+</sup></td>
                        <td align="left" valign="top" rowspan="1" colspan="1">17.1<break/>(21.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">21.6<break/>(46.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−4.5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−47.3 to 38.4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.6<break/>(3.2-29.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2.8<break/>(1.4-15.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4.8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−9.8 to 19.5</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> CD4<sup>+</sup></td>
                        <td align="left" valign="top" rowspan="1" colspan="1">112.5<break/>(80)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">124.3<break/>(126.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−11.8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−130.9 to 107.4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">119.3<break/>(46.1-156.3)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">48.4<break/>(40.7-223.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">70.8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−63.9 to 205.6</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> CD4<sup>+</sup>FOXP3<sup>+</sup></td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11.3<break/>(15.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">20.9<break/>(28.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−9.6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−36.1 to 16.9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5.7<break/>(2.1-13.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4.8<break/>(2.1-38.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−23.5 to 25.3</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> CD4<sup>+</sup>Ki67<sup>+</sup></td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.1<break/>(6.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.6<break/>(8.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−1.5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−9.3 to 6.3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.4<break/>(1.9–8.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.0<break/>(0.7-14.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−3.6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−13.3 to 6.1</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Myeloid-cell subsets</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n=15</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n=7</td>
                        <td align="left" valign="top" colspan="2" rowspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">n=15</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n=7</td>
                        <td align="left" valign="top" colspan="2" rowspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> CD15<sup>+</sup> granulocytes</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">79.3<break/>(136.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">51.0<break/>(63.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">28.3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−60.6 to 117.3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14.9<break/>(5.9-90.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">17.2<break/>(10.7-110.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−2.4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−78.3 to 73.5</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> CD15<sup>+</sup>ARG1<sup>+</sup></td>
                        <td align="left" valign="top" rowspan="1" colspan="1">42.0<break/>(67.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">22.1<break/>(26.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">19.9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−21.9 to 61.7</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4.2<break/>(1.8-71.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9.0<break/>(2.0-38.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−4.8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−44.6 to 35.0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> CD15<sup>+</sup>ARG1<sup>–</sup></td>
                        <td align="left" valign="top" rowspan="1" colspan="1">28.5<break/>(55.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">16.8<break/>(18.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11.6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−21.9 to 45.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11.9<break/>(2.1-32.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8.7<break/>(3.7-27.3)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−17.6 to 23.8</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> CD14<sup>+</sup> monocytes</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">355.2<break/>(245.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">555.9<break/>(530.3)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−200.7</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−694.6 to 293.2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">320.6<break/>(129.1-539.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">281.1<break/>(189.1-767.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">39.6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−393.1 to 472.2</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Macrophages</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n=<italic toggle="yes">12</italic></td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n=<italic toggle="yes">7</italic></td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">n=<italic toggle="yes">12</italic></td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n=<italic toggle="yes">7</italic></td>
                        <td align="left" valign="top" colspan="2" rowspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> Total macrophages</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1139.4<break/>(1417.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1020.8<break/>(879.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">118.6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−994.2 to 1231.5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">802.3<break/>(482.3-943.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">597.9<break/>(511.3-1564.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">204.4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−534.0 to 942.7</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> M1-polarized macrophages</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">365.9<break/>(785.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">133.5<break/>(103.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">232.4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−270.9 to 735.8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">101.3<break/>(52.4-180.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">107.6<break/>(44.6-205.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−6.3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−136.6 to 124.0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> M2-polarized macrophages</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">213.0<break/>(139.3)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">343.2<break/>(288.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−130.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−400.5 to 140.2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">199.5<break/>(107.4-239.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">325.6<break/>(70.1-487.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−126.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−407.7 to 155.5</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T3_FN1">
                      <p>CI, Confidence Interval; IQR, Interquartile range; SD, Standard Deviation.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Neoadjuvant CRT has also been linked to changes in the myeloid cell landscape of pancreatic cancer.<xref rid="R27" ref-type="bibr">27 28</xref> We therefore expanded our analysis to major monocyte/macrophage and granulocyte populations (<xref rid="T3" ref-type="table">table 3</xref> and <xref rid="F4" ref-type="fig">figure 4</xref>). Similar to the T-lymphocyte analyses, myeloid cell densities were similar in tumors for both study arms, although trends were noted. Overall, densities of CD15<sup>+</sup> granulocytes and CD14<sup>+</sup> monocytes were similar between treatment arms. In patients in Arm A, the median density of CD15<sup>+</sup>ARG1<sup>+</sup> immunosuppressive granulocytes was approximately half that of Arm B. Finally, densities of total macrophages (CD68<sup>+</sup>) and/or M2-polarized macrophages (CD163<sup>+</sup>CD68<sup>+</sup>) were determined. Although the IQRs overlapped substantially, the median number of total macrophages per mm<sup>2</sup> was slightly higher in Arm A tumors, but the median number of M2-polarized macrophages per mm<sup>2</sup> was slightly lower in Arm A tumors. The study was not powered for comparison between arms, and the range of values overlapped substantially for each of these cellular subsets.</p>
                <p>Beyond immune cell density, expression of PD-L1, the ligand for PD-1, could also be influenced by treatment with pembrolizumab. We therefore compared PD-L1 expression by immunohistochemistry between arms. As there is no consensus method for scoring PD-L1 expression in PDAC, we generated both TPS and CPS. Across 17 evaluable tumors, expression of PD-L1 was very low, with 88% of tumors showing a TPS of &lt;1% or a CPS of &lt;1 (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S3</xref>). While the two tumors with the highest PD-L1 expression levels were in Arm A, both of these tumors harbored TPS and CPS values that are low on an absolute scale, and there was no statistically significant difference in TPS or CPS between arms.</p>
              </sec>
              <sec id="s3-7">
                <title>Peripheral immune cell analyses</title>
                <p>We performed flow cytometry to immunophenotype peripheral T cells over the course of neoadjuvant therapy. To verify on-target binding of pembrolizumab, we determined that PD-1 staining on CD8<sup>+</sup>CD45RO<sup>+</sup> T cells was reduced in Arm A but not in Arm B, reflecting successful occlusion of the epitope by pembrolizumab. However, this effect was not uniform across the cohort, and three patients who did not derive clinical benefit showed an increase in PD-1<sup>+</sup> CD8<sup>+</sup> T cells (<xref rid="SP2" ref-type="supplementary-material">online supplemental figure S1A</xref>). In both arms, activated CD8<sup>+</sup> T cells, marked by co-expression of HLA-DR and CD38,<xref rid="R32" ref-type="bibr">32</xref> expanded during neoadjuvant therapy (mean of difference between end-of-treatment and baseline samples: 3.83 (95% CI: −0.02 to 7.68) in Arm A and 8.05 (95% CI: −0.88 to 16.98) in Arm B) (<xref rid="SP2" ref-type="supplementary-material">online supplemental figure S1B</xref>).</p>
                <supplementary-material id="SP2" position="float" content-type="local-data">
                  <object-id pub-id-type="doi">10.1136/jitc-2023-007586.supp2</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="SS2" xlink:href="jitc-2023-007586supp002.pdf" content-type="local-data"/>
                  </p>
                </supplementary-material>
                <p>CX3CR1 has also been reported to be associated with PD-1 blockade response.<xref rid="R33" ref-type="bibr">33</xref> Among the patients in our study, the fraction of CD8<sup>+</sup>CD45RO<sup>+</sup> T cells expressing CX3CR1 increased during neoadjuvant therapy (mean of difference between end-of-treatment and baseline samples: 9.44 (95% CI: 3.27 to 15.61)), although this increase was not seen when considering only Arm A (<xref rid="SP2" ref-type="supplementary-material">online supplemental figure S1C</xref>). Overall, we examined the density of HLA-DR, CD38, and CX3CR1—three flow cytometry-based biomarkers previously reported in the literature to describe checkpoint-blockade reactivated CD8<sup>+</sup> T cells—but could not identify changes in these markers that were dependent on the addition of pembrolizumab.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s4">
              <title>Discussion</title>
              <p>This multicenter Phase Ib/II clinical trial was designed to test the safety and immunologic effect of the combination of a neoadjuvant PD-1 inhibitor, pembrolizumab, and CRT in patients with resectable to borderline resectable PDAC. The combination of CRT and pembrolizumab in the neoadjuvant setting was well tolerated by patients: only one DLT (grade 3 transaminitis) was observed, and there was no difference in postoperative complications between treatment with the combination and treatment with CRT alone. However, the addition of pembrolizumab to CRT did not have a detectable effect on the density of several immune cell populations, including CD8<sup>+</sup> TILs, in the pancreatic cancer microenvironment. Furthermore, the median PFS, RFS, and OS durations of patients in both arms were similar.</p>
              <p>Although many strategies have been studied to improve the response of PDAC to immunotherapy, none have translated to clinical benefit.<xref rid="R34" ref-type="bibr">34</xref> The failure of these studies to demonstrate a meaningful clinical benefit could be attributed to several factors: (1) inclusion of gemcitabine-based over 5-fluorouracil-based regimens due to its better safety profile, with little data on how these two regimens differ in their immunomodulatory effects; (2) testing immune modulators in the advanced metastatic setting, where there is limited time to generate a meaningful immune response in a patient with an exhausted immune repertoire; (3) testing concurrent rather than sequential administration of chemotherapy and immune modulators when chemotherapy may have a detrimental effect on the T cells needed to generate an antitumor immune response; or (4) lack of tumor-specific T cells available for reactivation by immune checkpoint inhibitors, potentially due to profound defects in naïve T-cell priming. Although we have not addressed all these potential causative factors here, we evaluated PD-1 blockade in combination with 5-fluorouracil-based CRT in the non-metastatic setting and found no clear benefit over treatment with 5-fluorouracil-based CRT alone. Still unanswered is whether the results of immunotherapy can be improved with sequential administration of CRT and PD-1 blockade in this setting, use of different radiation strategies, or targeting subsets of patients who have high primed T-cell density.</p>
              <p>Notably, the density of CD8<sup>+</sup> TILs was similar across tumors from both arms. Although some potential differences were observed in myeloid cell populations, these were neither substantial nor definitive. In circulating immune cell populations, we found an increase in activation in a unique T-cell population (CD8<sup>+</sup>CD45RO<sup>+</sup>CX3CR1<sup>+</sup> cells), suggesting that modest CD8<sup>+</sup> T-cell activation can occur in the setting of CRT. However, the combination of pembrolizumab and CRT using capecitabine did not lead to statistically significant increases in T-cell activation in the blood or in the tumor, as measured by other standard markers and methodologies. It is possible that reactivated T cells in patients with PDAC display a different phenotype from reactivated T cells in patients with melanoma and other tumor types, or T cells in patients with PDAC express an exhaustion phenotype that cannot be reversed by the blockade of a single immune checkpoint.<xref rid="R35" ref-type="bibr">35</xref> Although pretreatment biopsies were not available for analysis of PD-L1 expression as a predictive biomarker in the study, the very low level of PD-L1 expression detected in treated tumors is consistent with other studies of PDAC and suggests that the PD-1/PD-L1 axis may not be highly operative in the PDAC immune microenvironment.<xref rid="R36" ref-type="bibr">36</xref> Immune checkpoint blockade may also be insufficient to change the PDAC TME to a favorable TME, and concurrent targeting immunosuppressive cells, including macrophages, may be needed.<xref rid="R37" ref-type="bibr">37</xref> However, the observed CD8<sup>+</sup> TIL data in this study population was more variable and skewed than predicted, resulting in wider CIs than originally assumed. Our findings, therefore, do not obviate the need for additional studies in this space.</p>
              <p>Neoadjuvant treatment with FOLFIRINOX has been associated with a favorable immune profile characterized by increased CD8<sup>+</sup> T lymphocytes, a shift in macrophage polarization toward an M1-like phenotype, and a reduction in immunosuppressive granulocytes in resectable PDAC.<xref rid="R28" ref-type="bibr">28</xref> These observations support our decision to amend the protocol to include patients who received prior FOLFIRINOX; however, we eventually had to close the study prematurely due to a slow accrual rate. The slow accrual rate can be explained, at least in part, by an evolving perception of the role of radiation in the neoadjuvant setting.<xref rid="R38" ref-type="bibr">38 39</xref> Although studying the biological effects of immunotherapy in PDAC is appropriate in the preoperative period and we have demonstrated that such studies may be conducted effectively outside the National Clinical Trials Network cooperative group mechanism, nimbler study designs, such as adaptive platform studies, should be used in the future to rapidly test multiple agents and combinations for biological effect. Further, to the extent that patients in this study were disproportionately white, future studies should place greater effort on the enrollment of a diverse patient sample (<xref rid="SP1" ref-type="supplementary-material">online supplemental table S4</xref>).</p>
              <p>Other limitations of this study pertain to our analysis of resected tumor specimens. For example, although our analysis of the TME used highly sensitive multiplexed immunofluorescence assays and targeted numerous broad classes of T cell and myeloid cells, these assays did not include markers for all potentially relevant immune cells and therefore could not capture all potential alterations that may occur due to treatment with a combination of CRT and pembrolizumab. In addition, although we profiled multiple regions from each tumor block to account for spatial heterogeneity, the total area of tissue analyzed per tumor was limited and may have influenced the accuracy of immune cell density estimates. Finally, while we appreciate the potential value of more comprehensive profiling of the patients and tumors in this study, the time period during which this trial was conducted predated widespread recognition of the value of somatic profiling and routine germline testing of patients with PDAC. Further, the limited tumor tissues available following clinical surgical pathology evaluation restricted our ability to perform next generation sequencing of tumor samples. In this regard, it must be noted that nearly all pancreatic adenocarcinomas have a low TMB<xref rid="R40" ref-type="bibr">40–43</xref> and typically share highly recurrent alterations in a small number of driver genes.<xref rid="R40" ref-type="bibr">40 41 44</xref> Indeed, in our prior studies of primary resected PDAC, across 300 tumors we did not find associations between the status of driver gene alterations (<italic toggle="yes">KRAS</italic>, <italic toggle="yes">TP53</italic>, <italic toggle="yes">CDKN2A</italic>, and <italic toggle="yes">SMAD4</italic>) or TMB and immune landscape as defined by density of more than a dozen separate lymphoid and myeloid immune cell populations.<xref rid="R27" ref-type="bibr">27 28 44</xref> Given the high rates of alterations in common driver genes, and the low rate of DNA mismatch repair (MMR) deficiency and hypermutation in PDAC, we believe that it is unlikely that our results are significantly influenced by specific combinations of driver genes or tumors with an elevated TMB. Nevertheless, we certainly encourage future studies of immune targeting agents to include MMR status, in addition to genomic driver status and TMB.</p>
              <p>In conclusion, the combination of CRT and pembrolizumab was found to be safe in the neoadjuvant setting in this randomized Phase Ib/II study. However, the addition of pembrolizumab to CRT did not have a detectable effect on several immune cell populations, including CD8<sup>+</sup> TILs, in the pancreatic cancer microenvironment. Future work regarding novel drug combinations should focus not only on priming adaptive immune responses but also targeting the PDAC immunosuppressive microenvironment.</p>
            </sec>
          </body>
          <back>
            <ack>
              <p>We thank Madison Semro, Associate Scientific Editor, and Sunita Patterson, Senior Scientific Editor, Research Medical Library, The University of Texas MD Anderson Cancer Center, for editing this article.</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> MHGK and OR conceived of and designed the presented trial, wrote the clinical protocol, provided support, accrued patients to the trial, helped write the manuscript, provided final review. GRP wrote the statistics for the trial, helped write the manuscript, provided final review. TB accrued patients to the trial, helped write the manuscript, provided final review. MJR accrued patients to the trial, helped write the manuscript, provided final review. BMW accrued patients to the trial, helped write the manuscript, provided final review. C-CS accrued patients to the trial, helped write the manuscript, provided final review. TSB-S accrued patients to the trial, helped write the manuscript, provided final review. RE generated data and provided analysis and interpretation thereof; helped write the manuscript, provided final review. NM accrued patients to the trial, helped write the manuscript, provided final review. ADC generated data and provided analysis and interpretation thereof; helped write the manuscript, provided final review. PL generated data and provided analysis and interpretation thereof; helped write the manuscript, provided final review. VC-R generated data and provided analysis and interpretation thereof; helped write the manuscript, provided final review. SR generated data and provided analysis and interpretation thereof; helped write the manuscript, provided final review. KP generated data and provided analysis and interpretation thereof; helped write the manuscript, provided final review. SKD generated data and provided analysis and interpretation thereof; helped write the manuscript, provided final review. JAN generated data and provided analysis and interpretation thereof; helped write the manuscript, provided final review. GRV (deceased) helped conceive of and design the trial, accrued patients to the trial. CLS accrued patients to the trial, helped write the manuscript, provided final review. OR accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> This clinical trial was funded by Merck as an investigator-initiated clinical trial (PI: OR). PL was supported by award Number T32GM007753 and T32GM144273 from the National Institute of General Medical Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health. VC-R was funded by a fellowship from the Pancreatic Cancer Action Network and the Francois Wallace Monahan Fund in loving memory of Michael Insel. SKD was funded by the DFCI Hale Family Center for Pancreatic Cancer Research and NIH grant U01 CA274276-01. BMW is supported by the Dana-Farber Cancer Institute Hale Family Center for Pancreatic Cancer Research, Lustgarten Foundation dedicated laboratory program, NIH grant U01 CA210171, NIH grant P50 CA127003, Stand Up to Cancer, Pancreatic Cancer Action Network, Noble Effort Fund, and Wexler Family Fund.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> This clinical trial was funded by Merck as an investigator-initiated clinical trial (PI: OR). SKD received research funding unrelated to this project from Eli Lilly and Company, Novartis Pharmaceuticals, Genocea, and Bristol-Myers Squibb and is a founder, science advisory board member and equity holder in Kojin. BMW has received consulting fees from Celgene, GRAIL, and Mirati, and research funding from Celgene, Eli Lilly, Novartis, and Revolution Medicines unrelated to this work. TSB-S received research Funding (to institution) unrelated to this project from Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, BMS. He received consulting fees to institution from Servier, Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merus, Merck KGA and Merck and to self from Stemline, AbbVie, Blueprint Medicines, Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, AstraZeneca, Deciphera, Zai Labs, Exelixis, Foundation Medicine and Sanofi. GlaxoSmithKline. TB serves on the IDMC/DSMB for the Valley Hospital, Fibrogen, Suzhou Kintor, AstraZeneca, Exelixis, Merck/Eisai, PanCan and 1Globe.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Supplemental material:</bold> This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p>
              </fn>
            </fn-group>
            <sec sec-type="data-availability">
              <title>Data availability statement</title>
              <p>Data are available upon reasonable request. All data is available upon request to the corresponding author.</p>
            </sec>
            <sec sec-type="ethics-statement">
              <title>Ethics statements</title>
              <sec>
                <title>Patient consent for publication</title>
                <p content-type="ethics-consent-to-publish">Not applicable.</p>
              </sec>
              <sec>
                <title>Ethics approval</title>
                <p content-type="ethics-approval">Ethics approval and consent to participate: Written informed consent was provided by all study participants, and the protocol was approved by the relevant IRB at each site. The study was conducted in accordance with International Ethical Guidelines for Biomedical Research involving Human Subjects. Participants gave informed consent to participate in the study before taking part.</p>
              </sec>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Siegel</surname><given-names>RL</given-names></string-name>, <string-name><surname>Miller</surname><given-names>KD</given-names></string-name>, <string-name><surname>Fuchs</surname><given-names>HE</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cancer statistics, 2021</article-title>. <source>CA Cancer J Clin</source><year>2021</year>;<volume>71</volume>:<fpage>7</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21654</pub-id><pub-id pub-id-type="pmid">33433946</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Groot</surname><given-names>VP</given-names></string-name>, <string-name><surname>Rezaee</surname><given-names>N</given-names></string-name>, <string-name><surname>Wu</surname><given-names>W</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma</article-title>. <source>Ann Surg</source><year>2018</year>;<volume>267</volume>:<fpage>936</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1097/SLA.0000000000002234</pub-id><pub-id pub-id-type="pmid">28338509</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khorana</surname><given-names>AA</given-names></string-name>, <string-name><surname>Mangu</surname><given-names>PB</given-names></string-name>, <string-name><surname>Berlin</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline</article-title>. <source>JCO</source><year>2016</year>;<volume>34</volume>:<fpage>2541</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2016.67.5553</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Couzin-Frankel</surname><given-names>J</given-names></string-name></person-group>. <article-title>Breakthrough of the year 2013. Cancer immunotherapy</article-title>. <source>Science</source><year>2013</year>;<volume>342</volume>:<fpage>1432</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1126/science.342.6165.1432</pub-id><pub-id pub-id-type="pmid">24357284</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gentzler</surname><given-names>R</given-names></string-name>, <string-name><surname>Hall</surname><given-names>R</given-names></string-name>, <string-name><surname>Kunk</surname><given-names>PR</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors</article-title>. <source>Immunotherapy</source><year>2016</year>;<volume>8</volume>:<fpage>583</fpage>–<lpage>600</lpage>. <pub-id pub-id-type="doi">10.2217/imt-2015-0029</pub-id><pub-id pub-id-type="pmid">27140411</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kunk</surname><given-names>PR</given-names></string-name>, <string-name><surname>Bauer</surname><given-names>TW</given-names></string-name>, <string-name><surname>Slingluff</surname><given-names>CL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>From bench to bedside a comprehensive review of pancreatic cancer Immunotherapy</article-title>. <source>J Immunother Cancer</source><year>2016</year>;<volume>4</volume>:<elocation-id>14</elocation-id>. <pub-id pub-id-type="doi">10.1186/s40425-016-0119-z</pub-id><pub-id pub-id-type="pmid">26981244</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bear</surname><given-names>AS</given-names></string-name>, <string-name><surname>Vonderheide</surname><given-names>RH</given-names></string-name>, <string-name><surname>O’Hara</surname><given-names>MH</given-names></string-name></person-group>. <article-title>Challenges and opportunities for pancreatic cancer immunotherapy</article-title>. <source>Cancer Cell</source><year>2020</year>;<volume>38</volume>:<fpage>788</fpage>–<lpage>802</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2020.08.004</pub-id><pub-id pub-id-type="pmid">32946773</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ho</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Jaffee</surname><given-names>EM</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>L</given-names></string-name></person-group>. <article-title>The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities</article-title>. <source>Nat Rev Clin Oncol</source><year>2020</year>;<volume>17</volume>:<fpage>527</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1038/s41571-020-0363-5</pub-id><pub-id pub-id-type="pmid">32398706</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clark</surname><given-names>CE</given-names></string-name>, <string-name><surname>Hingorani</surname><given-names>SR</given-names></string-name>, <string-name><surname>Mick</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Dynamics of the immune reaction to pancreatic cancer from inception to invasion</article-title>. <source>Cancer Res</source><year>2007</year>;<volume>67</volume>:<fpage>9518</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-0175</pub-id><pub-id pub-id-type="pmid">17909062</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chellappa</surname><given-names>S</given-names></string-name>, <string-name><surname>Hugenschmidt</surname><given-names>H</given-names></string-name>, <string-name><surname>Hagness</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Regulatory T cells that Co-express RORγt and Foxp3 are pro-inflammatory and immunosuppressive and expand in human pancreatic cancer</article-title>. <source>Oncoimmunology</source><year>2016</year>;<volume>5</volume>:<elocation-id>e1102828</elocation-id>. <pub-id pub-id-type="doi">10.1080/2162402X.2015.1102828</pub-id><pub-id pub-id-type="pmid">27141387</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bhowmick</surname><given-names>NA</given-names></string-name>, <string-name><surname>Neilson</surname><given-names>EG</given-names></string-name>, <string-name><surname>Moses</surname><given-names>HL</given-names></string-name></person-group>. <article-title>Stromal fibroblasts in cancer initiation and progression</article-title>. <source>Nature</source><year>2004</year>;<volume>432</volume>:<fpage>332</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nature03096</pub-id><pub-id pub-id-type="pmid">15549095</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Diaz</surname><given-names>LA</given-names></string-name>, <string-name><surname>Le</surname><given-names>DT</given-names></string-name></person-group>. <article-title>PD-1 blockade in tumors with mismatch-repair deficiency</article-title>. <source>N Engl J Med</source><year>2015</year>;<volume>373</volume>:<fpage>2509</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc1510353</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fukunaga</surname><given-names>A</given-names></string-name>, <string-name><surname>Miyamoto</surname><given-names>M</given-names></string-name>, <string-name><surname>Cho</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cd8+ tumor-infiltrating lymphocytes together with Cd4+ tumor-infiltrating lymphocytes and Dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma</article-title>. <source>Pancreas</source><year>2004</year>;<volume>28</volume>:<fpage>e26</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1097/00006676-200401000-00023</pub-id><pub-id pub-id-type="pmid">14707745</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Balachandran</surname><given-names>VP</given-names></string-name>, <string-name><surname>Łuksza</surname><given-names>M</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>JN</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer</article-title>. <source>Nature</source><year>2017</year>;<volume>551</volume>:<fpage>512</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/nature24462</pub-id><pub-id pub-id-type="pmid">29132146</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miksch</surname><given-names>RC</given-names></string-name>, <string-name><surname>Schoenberg</surname><given-names>MB</given-names></string-name>, <string-name><surname>Weniger</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Prognostic impact of tumor-infiltrating lymphocytes and neutrophils on survival of patients with Upfront resection of pancreatic cancer</article-title>. <source>Cancers (Basel)</source><year>2019</year>;<volume>11</volume>:<elocation-id>39</elocation-id>. <pub-id pub-id-type="doi">10.3390/cancers11010039</pub-id><pub-id pub-id-type="pmid">30609853</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stump</surname><given-names>CT</given-names></string-name>, <string-name><surname>Roehle</surname><given-names>K</given-names></string-name>, <string-name><surname>Manjarrez Orduno</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer</article-title>. <source>Open Biol</source><year>2021</year>;<volume>11</volume>:<fpage>210245</fpage>. <pub-id pub-id-type="doi">10.1098/rsob.210245</pub-id><pub-id pub-id-type="pmid">34784792</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yasmin-Karim</surname><given-names>S</given-names></string-name>, <string-name><surname>Bruck</surname><given-names>PT</given-names></string-name>, <string-name><surname>Moreau</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Radiation and local anti-Cd40 generate an effective</article-title>. <source>Front Immunol</source><year>2018</year>;<volume>9</volume>:<fpage>2030</fpage>.<pub-id pub-id-type="pmid">30245691</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Homma</surname><given-names>Y</given-names></string-name>, <string-name><surname>Taniguchi</surname><given-names>K</given-names></string-name>, <string-name><surname>Murakami</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma</article-title>. <source>Ann Surg Oncol</source><year>2014</year>;<volume>21</volume>:<fpage>670</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-013-3390-y</pub-id><pub-id pub-id-type="pmid">24310792</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schreiber</surname><given-names>RD</given-names></string-name>, <string-name><surname>Old</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Smyth</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion</article-title>. <source>Science</source><year>2011</year>;<volume>331</volume>:<fpage>1565</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1126/science.1203486</pub-id><pub-id pub-id-type="pmid">21436444</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>P</given-names></string-name>, <string-name><surname>Su</surname><given-names>DM</given-names></string-name>, <string-name><surname>Liang</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis</article-title>. <source>Mol Immunol</source><year>2008</year>;<volume>45</volume>:<fpage>1470</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2007.08.013</pub-id><pub-id pub-id-type="pmid">17920123</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Deng</surname><given-names>L</given-names></string-name>, <string-name><surname>Liang</surname><given-names>H</given-names></string-name>, <string-name><surname>Burnette</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice</article-title>. <source>J Clin Invest</source><year>2014</year>;<volume>124</volume>:<fpage>687</fpage>–<lpage>95</lpage>.:<elocation-id>67313</elocation-id>. <pub-id pub-id-type="doi">10.1172/JCI67313</pub-id><pub-id pub-id-type="pmid">24382348</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Katz</surname><given-names>MHG</given-names></string-name>, <string-name><surname>Shi</surname><given-names>Q</given-names></string-name>, <string-name><surname>Ahmad</surname><given-names>SA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101</article-title>. <source>JAMA Surg</source><year>2016</year>;<volume>151</volume>:<elocation-id>e161137</elocation-id>. <pub-id pub-id-type="doi">10.1001/jamasurg.2016.1137</pub-id><pub-id pub-id-type="pmid">27275632</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eisenhauer</surname><given-names>EA</given-names></string-name>, <string-name><surname>Therasse</surname><given-names>P</given-names></string-name>, <string-name><surname>Bogaerts</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title>. <source>Eur J Cancer</source><year>2009</year>;<volume>45</volume>:<fpage>228</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id><pub-id pub-id-type="pmid">19097774</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Edge</surname><given-names>SB</given-names></string-name>, <collab>American Joint Committee on Cancer</collab></person-group>. <source>AJCC cancer staging manual.</source><edition>7th ed</edition>. <publisher-loc>New York</publisher-loc>: <publisher-name>Springer</publisher-name>, <year>2010</year>.</mixed-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <mixed-citation publication-type="webpage"><article-title>Protocol for the examination of specimens from patients with carcinoma of the Exocrine Pancreas</article-title>. <year>2017</year>. <comment>Available</comment>: <uri xlink:href="https://documents.cap.org/protocols/cp-pancreas-exocrine-17protocol-4001.pdf">https://documents.cap.org/protocols/cp-pancreas-exocrine-17protocol-4001.pdf</uri></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>National Cancer Institute (U.S.)</collab></person-group>. <source>Common terminology criteria for adverse events (CTCAE)</source><edition>Rev. ed</edition>. <publisher-loc>Bethesda, Md</publisher-loc>: <publisher-name>U.S. Dept. of Health and Human Services, National Institutes of Health, National Cancer Institute</publisher-name>, <year>2009</year>.</mixed-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Väyrynen</surname><given-names>SA</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Composition, spatial characteristics, and prognostic significance of myeloid cell infiltration in pancreatic cancer</article-title>. <source>Clin Cancer Res</source><year>2021</year>;<volume>27</volume>:<fpage>1069</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-3141</pub-id><pub-id pub-id-type="pmid">33262135</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dias Costa</surname><given-names>A</given-names></string-name>, <string-name><surname>Väyrynen</surname><given-names>SA</given-names></string-name>, <string-name><surname>Chawla</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Neoadjuvant chemotherapy is associated with altered immune cell infiltration and an anti-tumorigenic microenvironment in resected pancreatic cancer</article-title>. <source>Clin Cancer Res</source><year>2022</year>;<volume>28</volume>:<fpage>5167</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-22-1125</pub-id><pub-id pub-id-type="pmid">36129461</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stokes</surname><given-names>JB</given-names></string-name>, <string-name><surname>Nolan</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Stelow</surname><given-names>EB</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer</article-title>. <source>Ann Surg Oncol</source><year>2011</year>;<volume>18</volume>:<fpage>619</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1245/s10434-010-1456-7</pub-id><pub-id pub-id-type="pmid">21213060</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hyder</surname><given-names>O</given-names></string-name>, <string-name><surname>Dodson</surname><given-names>RM</given-names></string-name>, <string-name><surname>Nathan</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Influence of patient, physician, and hospital factors on 30-day readmission following pancreatoduodenectomy in the United States</article-title>. <source>JAMA Surg</source><year>2013</year>;<volume>148</volume>:<fpage>1095</fpage>–<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1001/jamasurg.2013.2509</pub-id><pub-id pub-id-type="pmid">24108580</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khorana</surname><given-names>AA</given-names></string-name>, <string-name><surname>McKernin</surname><given-names>SE</given-names></string-name>, <string-name><surname>Berlin</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update</article-title>. <source>J Clin Oncol</source><year>2019</year>;<volume>37</volume>:<fpage>2082</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.19.00946</pub-id><pub-id pub-id-type="pmid">31180816</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kamphorst</surname><given-names>AO</given-names></string-name>, <string-name><surname>Pillai</surname><given-names>RN</given-names></string-name>, <string-name><surname>Yang</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Proliferation of PD-1+ Cd8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2017</year>;<volume>114</volume>:<fpage>4993</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1705327114</pub-id><pub-id pub-id-type="pmid">28446615</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yamauchi</surname><given-names>T</given-names></string-name>, <string-name><surname>Hoki</surname><given-names>T</given-names></string-name>, <string-name><surname>Oba</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>T-cell Cx3Cr1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors</article-title>. <source>Nat Commun</source><year>2021</year>;<volume>12</volume>:<elocation-id>1402</elocation-id>. <pub-id pub-id-type="doi">10.1038/s41467-021-21619-0</pub-id><pub-id pub-id-type="pmid">33658501</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Balachandran</surname><given-names>VP</given-names></string-name>, <string-name><surname>Beatty</surname><given-names>GL</given-names></string-name>, <string-name><surname>Dougan</surname><given-names>SK</given-names></string-name></person-group>. <article-title>Broadening the impact of Immunotherapy to pancreatic cancer: challenges and opportunities</article-title>. <source>Gastroenterology</source><year>2019</year>;<volume>156</volume>:<fpage>2056</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2018.12.038</pub-id><pub-id pub-id-type="pmid">30660727</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Freed-Pastor</surname><given-names>WA</given-names></string-name>, <string-name><surname>Lambert</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Ely</surname><given-names>ZA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The Cd155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer</article-title>. <source>Cancer Cell</source><year>2021</year>;<volume>39</volume>:<fpage>1342</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2021.07.007</pub-id><pub-id pub-id-type="pmid">34358448</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Soares</surname><given-names>KC</given-names></string-name>, <string-name><surname>Rucki</surname><given-names>AA</given-names></string-name>, <string-name><surname>Wu</surname><given-names>AA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors</article-title>. <source>J Immunother</source><year>2015</year>;<volume>38</volume>:<fpage>1</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1097/CJI.0000000000000062</pub-id><pub-id pub-id-type="pmid">25415283</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tu</surname><given-names>M</given-names></string-name>, <string-name><surname>Klein</surname><given-names>L</given-names></string-name>, <string-name><surname>Espinet</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>TNF-Α-producing macrophages determine subtype identity and prognosis via Ap1 enhancer reprogramming in pancreatic cancer</article-title>. <source>Nat Cancer</source><year>2021</year>;<volume>2</volume>:<fpage>1185</fpage>–<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1038/s43018-021-00258-w</pub-id><pub-id pub-id-type="pmid">35122059</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Katz</surname><given-names>MHG</given-names></string-name>, <string-name><surname>Shi</surname><given-names>Q</given-names></string-name>, <string-name><surname>Meyers</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus Hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial</article-title>. <source>JAMA Oncol</source><year>2022</year>;<volume>8</volume>:<fpage>1263</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1001/jamaoncol.2022.2319</pub-id><pub-id pub-id-type="pmid">35834226</pub-id></mixed-citation>
              </ref>
              <ref id="R39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Versteijne</surname><given-names>E</given-names></string-name>, <string-name><surname>Suker</surname><given-names>M</given-names></string-name>, <string-name><surname>Groothuis</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial</article-title>. <source>J Clin Oncol</source><year>2020</year>;<volume>38</volume>:<fpage>1763</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.19.02274</pub-id><pub-id pub-id-type="pmid">32105518</pub-id></mixed-citation>
              </ref>
              <ref id="R40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bailey</surname><given-names>P</given-names></string-name>, <string-name><surname>Chang</surname><given-names>DK</given-names></string-name>, <string-name><surname>Nones</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Genomic analyses identify molecular subtypes of pancreatic cancer</article-title>. <source>Nature</source><year>2016</year>;<volume>531</volume>:<fpage>47</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1038/nature16965</pub-id><pub-id pub-id-type="pmid">26909576</pub-id></mixed-citation>
              </ref>
              <ref id="R41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab></person-group>. <article-title>Integrated genomic characterization of pancreatic ductal adenocarcinoma</article-title>. <source>Cancer Cell</source><year>2017</year>;<volume>32</volume>:<fpage>185</fpage>–<lpage>203</lpage>.<pub-id pub-id-type="pmid">28810144</pub-id></mixed-citation>
              </ref>
              <ref id="R42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Singh</surname><given-names>H</given-names></string-name>, <string-name><surname>Keller</surname><given-names>RB</given-names></string-name>, <string-name><surname>Kapner</surname><given-names>KS</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer</article-title>. <source>Clin Cancer Res</source><year>2023</year>:<elocation-id>CCR-22-3930</elocation-id>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-22-3930</pub-id></mixed-citation>
              </ref>
              <ref id="R43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lawlor</surname><given-names>RT</given-names></string-name>, <string-name><surname>Mattiolo</surname><given-names>P</given-names></string-name>, <string-name><surname>Mafficini</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <comment>n.d.</comment><article-title>Tumor mutational burden as a potential biomarker for Immunotherapy in pancreatic cancer: systematic review and still-open questions</article-title>. <source>Cancers</source>;<volume>13</volume>:<fpage>3119</fpage>. <pub-id pub-id-type="doi">10.3390/cancers13133119</pub-id></mixed-citation>
              </ref>
              <ref id="R44">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qian</surname><given-names>ZR</given-names></string-name>, <string-name><surname>Rubinson</surname><given-names>DA</given-names></string-name>, <string-name><surname>Nowak</surname><given-names>JA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma</article-title>. <source>JAMA Oncol</source><year>2018</year>;<volume>4</volume>:<elocation-id>e173420</elocation-id>. <pub-id pub-id-type="doi">10.1001/jamaoncol.2017.3420</pub-id><pub-id pub-id-type="pmid">29098284</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
